While the increase of ATF6 and the decrease of IRE1α has been linked to resistance to cisplatin in NSCLC [155], in MM the low activity of both ATF6 and IRE-1α induces resistance to bortezomib [159]. The gene discussed is ERN1; the disease is non-small cell lung carcinoma.